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Abstract
In a number of cell types, elevation of intracellular cAMP concentrations antagonizes growth factor-induced mitogenesis
 .by abrogating the downstream signaling of RasGTP to extracellular-signal-regulated kinases Erk1,2 . We studied the effect
of elevation of cAMP concentrations on the IL-3-induced mitogenic response in the leukemic cell line AML193. We
 .observed that 8-bromo-cAMP 8-Br-cAMP had no inhibitory effect on the magnitude of this response. On the contrary,
8-Br-cAMP alone induced a proliferative response in these cells. 8-Br-cAMP activated Erk1,2 in these cells without
involvement of Shc phosphorylation. These findings suggest the presence of a novel cAMP-dependent signaling pathway in
AML193 cells, which activates Erk1,2 via a Shc-independent pathway and leads to the generation of a mitogenic response.
1. Introduction
Proliferation and differentiation of normal hemato-
poietic progenitors is regulated by a variety of
w xhematopoietic growth factors 1 . In vitro, inter-
 .leukin-3 IL-3 stimulates hematopoietic progenitors
to form colonies of mature cells, including granulo-
cytes, macrophages, erythrocytes and megakary-
ocytes. The biological effects of IL-3 are mediated by
binding of IL-3 to the specific high affinity IL-3-re-
 . w xceptor IL-3R 2 . This heterodimeric receptor is a
member of the hematopoietic receptor superfamily
w x3 . Previously it has been shown that like other
members of this receptor superfamily, IL-3 activates
a variety of SH2-containing signaling intermediates
w xof the p21RasrErk1,2 route, eg, Shc and Grb2 4 .
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Phosphorylated Shc and Grb2 form a bridge between
activated growth factor receptors and the guanine
nucleotide exchange factor sos, which mediates Ras-
GTP formation. Activation of p21Ras leads to stimu-
lation of the serinerthreonine kinase raf, that acti-
vates Erk1,2 smitogen-activated protein kinasess
.p42rp44 MAPK . Activated Erk1,2 translocate to the
nucleus and induce several transcription factors such
w xas the c-fos and c-jun genes 5 .
The interaction of the cAMP-dependent signaling
route and the ShcrRasrErk route appears to be
dependent on the cell type. In fibroblasts and
adipocytes, an increase of intracellular cAMP is gen-
erally associated with an inhibition of growth factor
w xinduced Erk1,2 activation and proliferation 6–10 .
On the other hand, cAMP induces phosphorylation of
w xErk1,2 in PC12 and L6 cells 11,12 and a mitogenic
w xresponse in thyroid cells 13 .
Apparently, cAMP can interfere with the prolifera-
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tive response of a cell either as a positive or a
negative regulator depending on the cell type. The
effect of cAMP in hematopoietic cell lines is also
variable. Whereas erythropoietin-stimulated prolifera-
tion was markedly inhibited by cAMP-analogues,
w xIL-3 stimulated growth was resistant to cAMP 14 .
Moreover, cAMP can promote cell survival and re-
w xtards apoptosis in an IL-3 dependent cell line 15 .
To study whether elevation of cAMP concentra-
tions results in modulation of the proliferative re-
sponse in leukemic cells in vitro, we examined the
mitogenic effect of cAMP-analogues in the IL-3 de-
pendent leukemic cell line AML193. We also investi-
gated the effect of cAMP on the activation status of
the ShcrRasrErk1,2 pathway.
Our results indicate that 8-Br-cAMP is a mitogenic
agent in AML193 cells and activates Erk1,2 without
the involvement of Shc phosphorylation.
2. Material and methods
2.1. Materials
8-Br-cAMP was purchased from Boehringer Man-
.nheim, Germany . O-Tetradecanoyl phorbol 13 ac-
 .  .etate TPA , 3-isobutyl-1-methyl-xanthine IBMX
 .and myelin basic protein MBP were obtained from
 . 32Sigma Chemicals Bornem, Belgium . g- P-ATP
 .from Amersham UK . IL-3 was kindly provided by
 .Sandoz Basel, Switzerland . Most of the cell culture
media was obtained from Gibco-BRL Breda, The
.Netherlands .
2.2. Cell culture and treatment
The human myeloid leukemic cell line AML 193
was obtained from the American Type Culture Col-
 .lection ATCC, Rockville, MD, USA . AML193 cells
were grown in IMDM containing 8% human serum
and 10 ngrml IL-3. For experiments, cells were
growth arrested for 24 h in IMDM supplemented
with 0.15% human albumin, prior to incubation with
various agents.
2.3. DNA synthesis assay
w3 xDNA synthesis was measured by H thymidine
3 .uptake experiments H-TdR . Growth-arrested cells
 4 .2=10 cells were incubated in six-fold in 150 ml
of IMDM q 0.15% albumin supplemented with
titrated concentrations of the various agents in 96-
wells plates for 30 h. Six hours before cell harvest, 1
w3 x 3mCi of H thymidine was added to each well. H-
TdR incorporation was measured by liquid scintilla-
tion counting.
2.4. Erk1,2 immunoblotting
Growth-arrested cells were treated with the indi-
cated growth factors. Cells were washed twice in
 .phosphate buffered saline PBS and SDS-sample
buffer was added to the pellet containing 10% glyc-
erol, 5% b-mercaptoethanol, 3% SDS, 100 mM Tri-
sPO pH 6.7 and 0.01% bromophenolblue. Proteins4
were separated on a 7.5% SDS-polyacrylamide gel
 .electrophoresis PAGE , blotted to nitrocellulose
 .Schleicher and Schuell, Dassel, Germany and incu-
bated with anti-Erk1 antiserum Santa Cruz, CA,
.USA . The phosphorylation status of the two iso-
forms of p44 and p42 Erk were detected by horse
 .radish peroxidase HRP -conjugated second antibod-
 .ies, followed by enhanced chemiluminescence ECL .
Activated Erk1,2 appeared as a band of retarded
mobility.
2.5. MBP kinase acti˝ity
Following stimulation the cells were washed in
PBS and lysis buffer was added containing 20 mM
Tris pH 8, 40 mM Na P O , 50 mM NaF, 5 mM4 2 7
 .MgCl , 0.1 mM Na VO , 10 mM EDTA, 1% vrv2 3 4
Triton X-100, 0.5% deoxycholate, 0.1% SDS and a
mixture of protease inhibitors. After lysis, 200 mg of
extracted protein was immunoprecipitated with anti-
Erk1 serum for 3 h. The precipitates were collected
using protein A-Sepharose Pharmacia Biotech,
.Roosendaal, The Netherlands and washed five times
in lysis buffer and once in kinase buffer 30 mM Tris,
.pH 8, 20 mM MgCl , 2 mM MnCl . Kinase activity2 2
was measured on the immune complex using 10 mM
ATP, 1 mCi 32P-ATP and 7.5 mg MBP for 30 min.
Proteins were resolved on a 15% SDS-PAGE, stained
with Coomassie blue and the MBP bands were
counted for reactivity.
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Fig. 1. Mitogenic responses of growth-arrested AML193 cells to
various agents in 3H-TdR uptake assay. Growth-arrested cells
were incubated in six-fold with indicated concentrations of 8-Br-
cAMP, 0.1 mM IBMX, 10 ngrml IL-3 or 10 ngrml TPA. Data
are expressed as percentages of non-treated growth-arrested cells.
This figure represents one of three independent experiments with
similar results.
2.6. Shc immunoprecipitation
After treatment of the cells, cells were washed and
lysed in buffer, containing 20 mM Tris pH 8.0, 137
mM NaCl, 10 mM EDTA, 100 mM NaF, 1% NP-40,
1 mM DTT, 10% glycerol, 2 mM Na VO and a3 4
mixture of proteinase inhibitors. The supernatant of
the lysates was incubated overnight with anti-Shc
antiserum kindly provided by Dr. J. Bos, Utrecht,
.The Netherlands . Protein A-Sepharose was added for
1 h and after extensive washing, bound proteins were
eluted by boiling in SDS-sample buffer. Proteins
were resolved on a 7.5% PAGE, transferred on a
nitrocellulose filter and incubated with 4G10 anti-
body Upstate Biotechnology, Lake Placid, NY,
.USA . The immunoprecipitates were detected by
HRP-conjugated second antibodies and visualized by
ECL.
3. Results
The proliferative response of growth-arrested
AML193 cells to various concentrations of 8-Br-
cAMP in relation to the stimulation by IL-3 is shown
in Fig. 1. A maximum in DNA synthesis of 226%
compared to non-stimulated cells was reached at 50
mM 8-Br-cAMP. The ED was approximately 1050
mM 8-Br-cAMP. A toxic effect on the cells was
observed above 2.5 mM 8-Br-cAMP. Treatment of
the cells with IBMX alone, a known enhancer of
cAMP levels in the cell by inhibiting cAMP break-
 .down, also stimulated DNA synthesis 160% . Deter-
mination of cell numbers confirmed that stimulation
with 8-Br-cAMP of growth-arrested cells, when fol-
lowed over a period of 4 days, indeed resulted in an
 .increase in cell number 130% , while non-treated
cells did not survive. We also examined whether
TPA, which activates protein kinase C and results in
activation of the Erk1,2 cascade, also induced a
mitogenic effect in these cells. Treatment of growth-
arrested AML193 cells with 10 ngrml TPA, how-
ever, inhibited the basal 3H-TdR incorporation. In-
creasing doses of TPA did not change this response.
To explore whether cAMP synergized the IL-3-in-
duced proliferative response, cells were incubated
with increasing concentrations of IL-3, either in the
Fig. 2. Effect of 8-Br-cAMP on IL-3 induced increase in 3H-TdR
incorporation in growth-arrested AML193 cells. Growth-arrested
cells were incubated in six-fold with 1 mM 8-Br-cAMP. After
one hour titrated concentrations of IL-3 were added. Data are
expressed as percentages of non-treated growth-arrested cells.
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Fig. 3. Effect of various concentrations of 8-Br-cAMP on the
phosphorylation of Erk1,2 in AML193 cells. Phosphorylation
 .was detected by Western blot with anti-Erk1 p42 antibody.
presence or absence of 1 mM 8-Br-cAMP. Addition
of 1 mM 8-Br-cAMP resulted in an additive effect on
the IL-3 induced 3H-TdR incorporation in AML193
 .cells Fig. 2 . Also at submaximal doses of 8-Br-
cAMP, a modest additive effect on the IL-3 induced
 .mitogenic response was observed data not shown .
Like many growth factors, IL-3 induced phospho-
rylation of Erk kinases in AML193 cells. We ob-
served that the maximal effect of IL-3 on Erk1,2
phosphorylation in growth-arrested AML193 cells
was time dependent and occurs in a time window of
5 to 15 min after addition of the growth factor. We
observed that 8-Br-cAMP also induced phosphoryla-
tion of Erk1,2 in these cells. Erk phosphorylation was
detectable at 0.1 mM 8-Br-cAMP and was maximal
at a concentration of 1 mM. The effect of 8-Br-cAMP
on Erk phosphorylation was more transient and the
maximal stimulation was seen between 1 and 5 min
 .Figs. 3 and 4 . TPA, a known strong activator of
Erk1,2 in many cells, also causes a very rapid but
more sustained activation of Erk kinases in AML193
 .cells data not shown . We subsequently examined
whether Erk phopshorylation, as reflected by the
mobility shift in Western blotting coincides with
activation of the Erk1,2 kinases. An in vitro kinase
Fig. 5. Stimulatory effect of IL-3 and 8-Br-cAMP on the activity
of Erk1 in AML193 cells. Growth-arrested cells were treated
 .with no factor for 10 minutes C , with 500 ngrml IL-3 for 10
min or with 1 mM 8-Br-cAMP for 5 min. Erk1 activity was
measured using exogenous MBP as a substrate as described in
Section 2. Data are means of"S.D. of three experiments.
assay using Erk1 from unstimulated and stimulated
cells was performed. For that, Erk1 was immunopre-
 .cipitated and myelin basic protein MBP was added
as substrate in the presence of radiolabeled ATP.
Both, IL-3 and cAMP, induced an increase in 32P
incorporation in MBP of respectively a 2.1- and
1.9-fold over values obtained from unstimulated cells
 .Fig. 5 .
In an approach to identify the signaling molecules
upstream of Erk1,2 which are involved in the activa-
tion of Erk by 8-Br-cAMP, we examined the effect of
8-Br-cAMP on the phosphorylation status of Shc-pro-
tein. Tyrosine phosphorylation of Shc-protein is a
common signaling event of cytokines upstream of
p21Ras and Erk1,2. Growth arrested AML193 cells
were treated with cAMP or IL-3 for the indicated
time periods. IL-3 caused a marked tyrosine phospho-
Fig. 4. Time course of activation of Erk1,2 in AML193 cells treated with 500 ngrml IL-3 or 1 mM 8-Br-cAMP.
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Fig. 6. Shc immunoprecipitates of AML193 cells. Growth-arre-
 .sted cells were incubated with no factor C , 500 ngrml IL-3 for
10 min, or 1 mM 8-Br-cAMP for 3 and 5 min. Western blot is
hybridized with antiphosphotyrosine antiserum.
rylation of Shc at 5 and 10 min after addition of the
growth factor. Treatment for 3 min or 5 min with
 .8-Br-cAMP showed no activation of Shc Fig. 6 .
These time periods were chosen based on Erk activa-
 .tion occurring within this time period Fig. 4 .
Reprobing the blot with anti-Shc showed equal load-
ing of protein in the lanes. We also examined the
effect of 8-Br-cAMP on Shc activation by measuring
ShcrGrb2 association. No ShcrGrb2 complex for-
mation was detected after treatment with 8-Br-cAMP
for 5 min nor at several time points before maximal
 .activation of Erk1,2 data not shown .
4. Discussion
Most growth factors and cytokines induce a mito-
genic response by activating the ShcrRasrErk path-
way. In many cell types, elevation of intracellular
cAMP concentrations inhibits the growth factor-in-
duced mitogenic signaling by abrogating the down-
w xstream signaling of RasGTP to Erk1,2 6–10 . In
these cells, eg fibroblasts, protein kinase A acts as a
 .negative regulator and protein kinase C PKC as a
positive regulator of growth-factor induced mitogene-
sis.
In our study we demonstrate that in the IL-3
dependent leukemic cell line AML193, cAMP does
not act via this common mechanism. Rather cAMP
itself induces a mitogenic response and activates
Erk1,2. These observations are consistent with the
stimulatory effect of elevation of intracellular cAMP
levels on MAPK activity in the rat pheochromocy-
w xtoma PC12 cells 11 . To determine at which level in
the ShcrRasrErk pathway cAMP provides a stimula-
tory signal in AML193 cells, we determined the
effect of elevating intacellular cAMP levels on Shc
phosphorylation. No Shc phosphorylation was de-
tected after treatment with 8-Br-cAMP indicating an
interference of the ShcrRasrErk pathway by cAMP
downstream of Shc. It is conceivable that 8-Br-cAMP
interferes with raf-kinase, since signaling studies in
PC12 cells and fibroblasts have demonstrated that in
these cells cAMP can interfere with Erk1,2 at this
level. However, the precise mechanism of this inter-
w xaction still has to be elucidated 6,16 .
PKC can also activate Erk1,2 in many cell types.
TPA, being a potent activator of PKC, was found to
be a potent activator of Erk kinases in AML193 cells,
but, remarkably TPA treatment did not induce a
mitogenic response in these cells. These observations
imply that Erk activation alone is not sufficient for
the proliferative response in AML193 cells and that
additional signals initiated by cAMP are required.
Another possibility is that TPA induces an inhibitory
growth signal in these cells due to the difference in
kinetics of the TPA- and cAMP-induced activation of
Erks.
Whether the mitogenic effect of 8-Br-cAMP in
leukemic cells is a general feature is not clear yet. In
the human leukemic cell line KG1 we also observed
in the absence of stimulatory serum factors, a modest
proliferative effect of 8-Br-cAMP, whereas no mito-
genic effect in response to 8-Br-cAMP was detected
w xin HL60 cells. Interestingly, Berridge 15 has
demonstrated in the IL-3 dependent leukemic cell
line, 32D, that cAMP-analogues can act as an anti-
apoptotic agent.
Our data confirm that the ShcrRasrErk1,2 signal-
ing pathway is susceptible to modulation. In most cell
types, cAMP leads to an abrogation of signaling by
interfering with transmission of proliferative signals
generated by RasGTP. In AML193, an opposite situa-
tion is seen. 8-Br-cAMP activates in this cell line the
Erk 1,2 pathway without the involvement of upstream
Shc phosphorylation events. Moreover, our data iden-
tify 8-Br-cAMP to be a mitogenic agent in this cell
line, which seems to act at least in part by activating
the Erk1,2.
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